Starting chemotherapy along with androgen deprivation therapy (ADT) in patients newly diagnosed with metastatic prostate cancer (mPCa) improved median overall survival by more than 13 months, according to a study presented at the American Society of Clinical Oncology annual meeting in Chicago.
In a press conference, investigator Christopher J. Sweeney, MBBS, of the Dana-Farber Cancer Institute in Boston, observed, “This is one of the biggest improvements in survival we have seen in a trial involving patients with an adult metastatic solid tumor.”
The study included 790 patients randomized to receive ADT alone (393 patients) or ADT plus docetaxel (397 patients). Subjects had a median age of 63 years. A planned interim analysis showed that the median overall survival (OS) was 44 months in the ADT-only arm compared with 57.6 months in the ADT plus docetaxel arm, a difference that translated into a significant 39% decreased risk of death.
Among men with high-volume disease, the median OS in the ADT-only and combination arms was 32.2 months and 49.2 months, respectively, a 17-month difference that translated into a significant 40% decreased risk of death. In patients with low-volume disease, median OS had not been reached at the time of the analysis, according to investigators.